Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
about
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.Production and characterization of a peptide-based monoclonal antibody against CD44 variant 6.PET tracers based on Zirconium-89.Identification and immunotherapeutic targeting of antigens induced by chemotherapy.In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
P2860
Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Selection of monoclonal antibo ...... head and neck cancer patients.
@en
Selection of monoclonal antibo ...... head and neck cancer patients.
@nl
type
label
Selection of monoclonal antibo ...... head and neck cancer patients.
@en
Selection of monoclonal antibo ...... head and neck cancer patients.
@nl
prefLabel
Selection of monoclonal antibo ...... head and neck cancer patients.
@en
Selection of monoclonal antibo ...... head and neck cancer patients.
@nl
P2093
P2860
P356
P1476
Selection of monoclonal antibo ...... head and neck cancer patients.
@en
P2093
Plaizier MA
den Hollander W
van Dongen GA
van Kamp GJ
P2860
P2888
P304
P356
10.1038/BJC.1997.179
P407
P577
1997-01-01T00:00:00Z